Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2022 Earnings Conference Call August 10, 2022 5:00 PM ET Company Participants Paul Goodson - Head, IR Wenbin Jiang - President, CEO and Chairman Patrik Jeanmonod - CFO Conference Call Participants Max Masucci - Cowen & Company Matt Sykes - Goldman Sachs David Westenberg - Piper Sandler Tejas Savant - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Cytek Biosciences' Second Quarter 2022 Earnings Conference Call. At this time, all partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRAN ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2022 Earnings Conference Call May 11, 2022 5:00 PM ET Company Participants Paul Goodson - Head, IR Wenbin Jiang - President, CEO & Chairman Patrik Jeanmonod - CFO Conference Call Participants Max Masucci - Cowen and Company Matthew Sykes - Goldman Sachs Group David Westenberg - Piper Sandler & Co. Tejas Savant - Morgan Stanley Operator Thank you for standing by, and welcome to the Cytek Biosciences First Quarter 2022 Earnings Conference Call. [Operator Instructions]. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2021 Earnings Conference Call February 23, 2022 5:00 PM ET Company Participants Alex Khan - Investor Relations Wenbin Jiang - Chief Executive Officer Patrik Jeanmonod - Chief Financial Officer Allen Poirson - Senior Vice President, Marketing and Corporate Development Conference Call Participants Tejas Savant - Morgan Stanley Dave Delahunt - Goldman Sachs David Westenberg - Piper Sandler Operator Thank you for standing by. And welcome to the Cytek Biosciences Fourth Q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share CTKB The Nasdaq Global Select Market Emerging growth company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2021 Earnings Conference Call November 8, 2021 4:30 PM ET Company Participants Wenbin Jiang - Chief Executive Officer Patrik Jeanmonod - Chief Financial Officer Conference Call Participants Max Masucci - Cowen and Company Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share CTKB The Nasdaq Global Select Market Emerging growth company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...